My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

83.82 -1.06 (-1.25%)

Streaming Delayed Price Updated: 11:46 AM EDT, Jul 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Where Cytokinetics Stands With Analysts ↗

August 22, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023 ↗

August 15, 2023

Via Benzinga

Where Cytokinetics Stands With Analysts ↗

August 04, 2023

Via Benzinga

Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday ↗

August 04, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

11 Analysts Have This to Say About Cytokinetics ↗

June 20, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 26, 2023

Wednesday saw 59 companies set new 52-week lows.

Via Benzinga

5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies ↗

June 20, 2023

Via Benzinga

What 20 Analyst Ratings Have To Say About Cytokinetics ↗

May 22, 2023

Via Benzinga

18 Analysts Have This to Say About Cytokinetics ↗

May 05, 2023

Via Benzinga

Cytokinetics: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Analyst Ratings for Cytokinetics ↗

April 18, 2023

Via Benzinga

Analyst Expectations for Cytokinetics's Future ↗

March 31, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility ↗

March 31, 2023

Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical...

Via Benzinga

Analyst Ratings for Cytokinetics ↗

March 06, 2023

Via Benzinga

FDA Rejects Cytokinetics' Heart Failure Treatment Candidate ↗

March 01, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Cytokinetics's Earnings: A Preview ↗

February 28, 2023

Via Benzinga

Analyst Ratings for Cytokinetics ↗

February 17, 2023

Via Benzinga

Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle ↗

March 06, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023 ↗

February 17, 2023

Via Benzinga

A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? ↗

February 17, 2023

The company's biggest moneymakers are soon to lose patent protection.

Via Investor's Business Daily

Analyst Ratings for Cytokinetics ↗

December 20, 2022

Via Benzinga

Expert Ratings for Cytokinetics ↗

December 20, 2022

Via Benzinga

What 7 Analyst Ratings Have To Say About Cytokinetics ↗

December 20, 2022

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗

December 23, 2022

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 ↗

December 20, 2022

Via Benzinga

Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 14, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition